Assessing Vulnerability and Outcomes of Intracranial Atherosclerotic Plaques

Xuanwu Hospital, Beijing3,849 enrolled

Overview

This prospective cohort study aims to establish a large-scale cohort for primary stroke prevention in asymptomatic intracranial atherosclerosis (ICAS). Objectives include: characterizing risk factor and stenotic artery distributions; determining optimal TCD screening sentinel arteries; observing plaque progression/regression via HR-MRI; establishing vulnerable plaque evaluation systems through stroke event follow-up; and developing cognitive decline prediction models integrating hemodynamic parameters. All procedures (TCD, HR-MRI, neuropsychological assessments) are routine clinical examinations with minimal risk. Participation is voluntary. Initial TCD and qualifying HR-MRI scans incur standard fees; all follow-up imaging and neuropsychological assessments post-enrollment are provided free of charge.

Study Type

OBSERVATIONAL

Enrollment

3,849

Conditions

Asymptomatic Intracranial Atherosclerotic Stenosis Patients

Interventions

Progression and Outcome of Intracranial AtherosclerosisDIAGNOSTIC_TEST

"Progression and Outcome of Intracranial Atherosclerosis" is the primary endpoint; all others are secondary endpoints. Stroke defined as any stroke and new ipsilateral stroke (including ischemic and hemorrhagic stroke) associated with vascular stenosis.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Intracranial arterial stenosis confirmed by transcranial Doppler (TCD), clinically suspected to be of atherosclerotic origin * No history of stroke or transient ischemic attack (TIA) * Adequate temporal bone acoustic window penetrability Exclusion Criteria: * Clinically diagnosed non-atherosclerotic etiology-related intracranial arterial stenosis * Poor temporal bone acoustic window penetrability * Loss to follow-up

Outcomes

Primary Outcomes

Number of participants with Progression of Intracranial Atherosclerosis

Number of participants with Progression of intracranial atherosclerosis encompass intracranial arterial stenosis, development of new stenoses, worsening of existing stenoses, as well as decrease, regression, or resolution of stenosis.

Time frame: 4 years

Secondary Outcomes

Number of participants with Clinical adverse event

Clinical adverse events include stroke, death, myocardial infarction, onset and progression of cognitive impairment and worsening of functional outcomes (mRS score ≥2)